Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears KN-002 IND for Asthma by Kinaset Therapeutics
Details : KN-002 (frevecitinib) is a JAK1/2/3 inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with asthma.
Product Name : KN-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Frevecitinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
